Skip to content

Study · Measured the body's own peptide · 1992

2 results

Activation of kappa-opioid receptors inhibits depolarisation-evoked exocytosis but not the rise in intracellular Ca2+ in secretory nerve terminals of the neurohypophysis.

Kato M, Chapman C, Bicknell RJ

Brain research1 Mar 1992Cited by 25 (Europe PMC)

PMID1353398 (opens in a new tab)DOI10.1016/0006-8993(92)90810-v (opens in a new tab)PepBankPUB-01353398
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelEx vivo tissueMechanism

    In isolated neurohypophysial nerve terminals, the kappa-opioid agonist DPDYN reduced K+-evoked secretion of the body's own oxytocin by 40-90%.

    In plain wordsIn isolated nerve endings, a kappa-opioid agonist reduced release of the body's own oxytocin.

    Peptide
    Oxytocin
    Outcome
    DecreaseK+-evoked oxytocin secretion with kappa agonist DPDYN
    Study

    n: not reported in source

    Comparator
    K+ depolarisation without agonist
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Measurements

    Inhibition of oxytocin secretion
    40 to 90%
    DPDYN, K+ evoked

    Source sentences

    Summary
    The selective kappa-receptor agonist D-Pro10 Dynorphin A 1-11 (DPDYN) substantially inhibited K+ evoked secretion of oxytocin by 40-90%
    1 context sentence
    Summary · context
    Using a preparation of isolated terminals from the neurohypophysis we studied kappa-opioid effects on secretion of oxytocin and vasopressin and on intracellular Ca2+ concentration ([Ca2+]i) measured fluorimetrically or using digital video imaging with Fura-2.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02LabEndogenous levelEx vivo tissueMechanism

    In isolated neurohypophysial nerve terminals, nicardipine inhibited evoked secretion of the body's own oxytocin.

    In plain wordsIn isolated nerve endings, a calcium-channel blocker reduced release of the body's own oxytocin.

    Peptide
    Oxytocin
    Outcome
    DecreaseK+-evoked oxytocin secretion with nicardipine
    Study

    n: not reported in source

    Comparator
    K+ depolarisation without antagonist
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The dihydropyridine Ca(2+)-channel antagonist nicardipine reduced [Ca2+]i responses to K(+)-depolarisation (30-40 mM K+) by 55-75% and inhibited evoked secretion of oxytocin and vasopressin to a similar extent.
    1 context sentence
    Summary · context
    Using a preparation of isolated terminals from the neurohypophysis we studied kappa-opioid effects on secretion of oxytocin and vasopressin and on intracellular Ca2+ concentration ([Ca2+]i) measured fluorimetrically or using digital video imaging with Fura-2.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.